Physician profile
Ken Yamaguchi
NPI 1376561001
$1,673,033.00
in general payments reported to CMS, 2019-2025
5 companies · $367K in 2025
The $367K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $135K · 2021: $165K · 2022: $297K · 2023: $280K · 2024: $305K · 2025: $367K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $927K · Consulting Fee: $21K · Travel and Lodging: $2,368 · Food and Beverage: $1,165 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $926,505.42 |
| Consulting Fee | $21,000.00 |
| Travel and Lodging | $2,367.60 |
| Food and Beverage | $1,165.11 |
| Education | $160.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,198,641.75 | 2019-2025 | Identity, Trabecular Metal, Comprehensive Shoulder System |
| Stryker Corporation | $248,308.63 | 2021-2023 | Latitude Ev |
| Wright Medical Technology, INC. | $225,774.65 | 2019-2020 | |
| Exactech, INC. | $160.49 | 2023 | |
| Medacta USA, INC. | $147.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Yamaguchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.